Results 181 to 190 of about 1,271,462 (341)

Reduced Tumor Mass, Reduction and Stabilization of Cancer Markers, Through Adjunct Use of CellSonic VIPP in the Treatment of Stage IV Choriocarcinoma [PDF]

Andrew Hague
openalex   +1 more source

Integrating Classical Tumor Markers and Systemic Inflammatory Indices for Enhanced Biological Profiling in Testicular Neoplasms. [PDF]

Cureus
Portakal S, Cakiroglu B, Solak M.
europepmc   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Identification of tumor initiating cells and early marker genes in normal colonic epithelium that lead to neoplastic transformation [PDF]

Sangeeta Jaiswal, Stephanie The, Tse-Shao Chang, Jiaqi Shi, Thomas D. Wang   +4 more
openalex   +1 more source

Significance of Serum Tumor Markers in Esophageal and Gastric Cancers: A Systematic Literature Review. [PDF]

Ann Gastroenterol Surg
Matsumoto Y, Toyozumi T, Shimada H.
europepmc   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Supplementary Figures 1-6, Tables 1-5 from Outgrowth of Drug-Resistant Carcinomas Expressing Markers of Tumor Aggression after Long-term TβRI/II Kinase Inhibition with LY2109761

, 2023
Erin C. Connolly, Elise F. Saunier, David A. Quigley, Minh Thu Luu, Angela De Sapio, Byron Hann, Jonathan M. Yingling, Rosemary J. Akhurst   +7 more
openalex   +2 more sources

Comparison of the clinical usefulness of CXCL-8 and common clinical tumor markers for esophageal cancer diagnosis. [PDF]

PeerJ
Lu P, Xu B, Zhang X, Zheng C, Chen X, Zhang J, Cao Y, Huang Z.   +7 more
europepmc   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Supplementary Figure 2 from Universal Marker and Detection Tool for Human Sarcoma Circulating Tumor Cells

, 2023
Arun Satelli, Abhisek Mitra, Jeffry J. Cutrera, Marcos Devarie, Xueqing Xia, Davis R. Ingram, Denada Dibra, Neeta Somaiah, Keila E. Torres, Vinod Ravi, Joseph A. Ludwig, Eugenie S. Kleinerman, Shulin Li   +12 more
openalex   +1 more source